+

WO1994005269A1 - Inhibiteurs peptidiques de fixation de la selectine - Google Patents

Inhibiteurs peptidiques de fixation de la selectine Download PDF

Info

Publication number
WO1994005269A1
WO1994005269A1 PCT/US1993/008436 US9308436W WO9405269A1 WO 1994005269 A1 WO1994005269 A1 WO 1994005269A1 US 9308436 W US9308436 W US 9308436W WO 9405269 A1 WO9405269 A1 WO 9405269A1
Authority
WO
WIPO (PCT)
Prior art keywords
selectin
peptide
host
arg
ser
Prior art date
Application number
PCT/US1993/008436
Other languages
English (en)
Inventor
George A. Heavner
Original Assignee
Centocor, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor, Inc. filed Critical Centocor, Inc.
Publication of WO1994005269A1 publication Critical patent/WO1994005269A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This application is a continuation-in-part of United States Serial No. 941,649, filed on September 8, 1992.
  • This invention relates to peptides which inhibit binding of selectins such as P-selectin, E-selectin and L-selectin.
  • the adherence of platelets and leukocytes to vascular surfaces is a critical component of the inflammatory response and is part of a complex series of reactions involving the simultaneous and interrelated activation of the complement, coagulation, and immune systems.
  • the complement proteins collectively play a leading role in the immune system, both in the identification and in the removal of foreign substances and immune complexes, as reviewed by Muller-Eberhard, H.J., Ann. Rev. Biochem. 57:
  • C3 and C4 proteins Central to the complement system are the C3 and C4 proteins, which when activated covalently attach to nearby targets, marking them for clearance.
  • C3 and C4 proteins Central to the complement system are the C3 and C4 proteins, which when activated covalently attach to nearby targets, marking them for clearance.
  • a remarkable family of soluble and membrane-bound regulatory proteins has evolved, each of which interacts with activated C3 and/or C4 derivatives.
  • the coagulation and inflammatory pathways are regulated in a coordinate fashion in response to tissue damage. For example, in addition to becoming adhesive for leukocytes, activated endothelial cells express tissue factor on the cell surface and decrease their surface expression of thrombomodulin, leading to a net facilitation of coagulation reactions on the cell surface. In some cases, a single receptor can be involved in both inflammatory and coagulation processes .
  • Leukocyte adherence to vascular endothelium is a key initial step in migration of leukocytes to tissues in response to microbial invasion.
  • a class of inducible leukocyte receptors the CD11-CD18 molecules, are thought to have some role in adherence to endothelium, mechanisms of equal or even greater importance for leukocyte adherence appear to be due to inducible changes in the endothelium itself.
  • Activated platelets have also been shown to interact with both neutrophils and monocytes in vi tro .
  • the interaction of platelets with monocytes may be mediated in part by the binding of thrombospondin to platelets and monocytes, although other mechanisms have not been excluded.
  • the mechanisms for the binding of neutrophils to activated platelets are not well understood, except that it is known that divalent cations are required.
  • platelets In response to vascular injury, platelets are known to adhere to subendothelial surfaces, become activated, and support coagulation.
  • Platelets and other cells may also play an important role in the recruitment of leukocytes into the wound in order to contain microbial invasion.
  • Endothelium exposed to "rapid" activators such as thrombin and histamine becomes adhesive for neutrophils within two to ten minutes, while endothelium exposed to cytokines such as tumor necrosis factor and interleukin-1 becomes adhesive after one to six hours.
  • the rapid endothelial-dependent leukocyte adhesion has been associated with expression of the lipid mediator platelet activating factor (PAF) on the cell surface, and presumably, the appearance of other endothelial surface receptors .
  • PAF lipid mediator platelet activating factor
  • the slower cytokine-inducible endothelial adhesion for leukocytes is mediated, at least in part, by E-selectin that is synthesized by endothelial cells after exposure to cytokines and then transported to the cell surface, where it binds neutrophils.
  • E-selectin that is synthesized by endothelial cells after exposure to cytokines and then transported to the cell surface, where it binds neutrophils.
  • L-selectin a peripheral lymph node homing receptor
  • the murine Mel 14 antigen is another structure on neutrophils, monocytes, and lymphocytes that binds lymphocytes to high endothelial venules in peripheral lymph nodes.
  • the characterization and cloning of the protein is reviewed by Lasky, et al . , Cell 56, 1045-1055 (1989) (mouse) and Tedder, et al. , J. Exp. Med. 170, 123-133 (1989) .
  • P-selectin also known as GMP-140 (granule membrane protein 140) , or PADGEM
  • GMP-140 granule membrane protein 140
  • PADGEM granule membrane protein 140
  • SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
  • GMP-140 P-selectin
  • the cDNA-derived amino acid sequence reported by Johnston, et al . , in Cell 56, 1033-1044 (March 24 1989) , and in U.S. Serial No. 07/320,408 filed March 8, 1989, indicates that it contains a number of modular domains that are likely to fold independently. Beginning at the N-terminus, these include a "lectin” domain, an "EGF” domain, nine tandem consensus repeats similar to those in complement binding proteins, a transmembrane domain (except in a soluble form that appears to result from differential splicing) , and a cytoplasmic tail.
  • lymphocytes (Larsen, et al . Cell 59:305-312 (1989)) ; Moore, et al. , J. Cell Biol. 112:491-499 (1991)) , and perhaps a subset of lymphocytes
  • GMP- 140 can serve as a receptor for leukocytes following its rapid mobilization to the surfaces of platelets and endothelial cells stimulated with agonists such as thrombin. This role in leukocyte recruitment may be important in hemostatic and inflammatory processes in both physiologic and pathologic states.
  • E-selectin is not present in unstimulated endothelium. However, when endothelium is exposed to cytokines such as tumor necrosis factor of interleukin-1, the gene for E-selectin is transcribed, producing RNA which in turn is translated into protein. The result is that E- selectin is expressed on the surface of endothelial cells one to four hours after exposure to cytokines, as reported by Bevilacqua et al. , Proc. atl .Acad.Sci .USA 84: 9238-9242 (1987) (in contrast to P-selectin, which is stored in granules and presented on the cell surface within seconds after activation) .
  • E-selectin has been shown to mediate the adherence of neutrophils to cytokine-treated endothelium and thus appears to be important in allowing leukocytes to migrate across cytokine-stimulated endothelium into tissues.
  • the cDNA-derived primary structure of E-selectin indicates that it contains a "lectin" domain, an EGF domain, and six (instead of the nine in P-selectin) repeats similar to those of complement-regulatory proteins, a transmembrane domain, and a short cytoplasmic tail.
  • P-selectin and E-selectin There is extensive sequence homology between P-selectin and E-selectin throughout both proteins, but the similarity is particularly striking in the lectin and EGF domains.
  • Homing receptors are lymphocyte surface structures that allow lymphocytes to bind to specialized endothelial cells in lymphatic tissues, termed high endothelial cells or high endothelial venules (reviewed by Yednock and Rose, Advances in Immunology, vol. 44, F.I. Dixon, ed. , 313-378 (Academic Press, New York 1989) .
  • This binding allows lymphocytes to migrate across the endothelium into the lymphatic tissues where they are exposed to processed antigens. The lymphocytes then re-enter the blood through the lymphatic system.
  • L-selectin a lymphocyte homing receptor, contains a lectin domain, an EGF domain, two complement-binding repeats, a transmembrane domain, and a short cytoplasmic tail. L-selectin also shares extensive sequence homology with P-selectin, particularly in the lectin and EGF domains.
  • platelets in response to vascular injury, platelets are known to adhere to subendothelial surfaces, become activated, and support coagulation. Platelets and other cells may also play an important role in the recruitment of leukocytes into the wound in order to contain microbial invasion. Conversely, leukocytes may recruit platelets into tissues at sites of inflammation, as reported by Issekutz, et al . , Lab. Invest. 49:716 (1983) .
  • the coagulation and inflammatory pathways are regulated in a coordinate fashion in response to tissue damage.
  • activated endothelial cells express tissue factor on the cell surface and decrease their surface expression of thrombomodulin, leading to a net facilitation of coagulation reactions on the cell surface.
  • a single receptor can be involved in both inflammatory and coagulation processes .
  • Proteins involved in the hemostatic and inflammatory pathways are of interest for diagnostic purposes and treatment of human disorders.
  • proteins therapeutically Proteins are usually expensive to produce in quantities sufficient for administration to a patient.
  • peptides which can fa- prepared synthetically, having activity at least equal tc, greater than, the peptides derived from the protein itseli It is therefore an object of the present invent:c: to provide peptides interacting with cells recognized by selectins, including P-selectin, E-selectin, and L-selectir.
  • This invention relates to novel peptides having as their core region portions of the 11-18 amino acid sequence of P-selectin, E-selectin or L-selectin. More specifically, this invention relates to novel peptides of the formula:
  • X' is a C-terminus amino acid linear sequence of from zero to 10 amino acids, and R 2 is a moiety attached to the carboxyl carbon of X or the carboxyl carbon of the adjacent amino acid if X is zero;
  • A is D- or L-serine, D- or L-asparagine, or D- or
  • B is D- or L-tryptophan or D- or L-tyrosine
  • C is D- or L-asparagine or D- or L-glutamine, or D- or L-aspartic acid
  • D is D- or L-isoleucine or D- or L-arginine, or D- or L-glutamic acid;
  • E is D- or L-serine or D- or L-alanine
  • F is D- or L-arginine or D- or L-serine
  • G is D- or L-arginine, D- or L-lysine or D- or L- alanine;
  • H is D- or L-phenylalanine or D- or L-tyrosine
  • R 1 is hydrogen (signifying a free N-terminal group) , lower alkyl, aryl, formyl, alkanoyl, aroyl, alkyloxycarbonyl or arroyloxycarbonyl;
  • R 2 is OH (signifying a free C-terminal carboxylic acid) , OR 3 , signifying ester, where R 3 is lower alkyl or aryl or R 2 is NR 5 R 6 where R 5 and R 6 are each selected independently from hydrogen, lower alkyl, aryl or cyclic alkyl; provided that, when -X-A-B-C-D-E-F-G-H-X 1 is Ser-Thr-Lys-Ala-Tyr-Ser- Trp-Asn-Ile-Ser-Arg-Lys-Tyr (SEQ ID NO:l) , then R 2 is other than OH.
  • the peptides of Formula I has as its core region the 11-18 amino acid sequence of the selectins.
  • Residue 1 is defined as the N-terminus of the mature protein after the cleavage of the signal peptide.
  • the peptides of Formula I should inhibit the binding of neutrophils to P-selectin in concentrations of peptide ranging from about 10 to about 1500 ⁇ M. Tests also indicate that alterations within the core sequence, as well as N-terminal and C-terminal flanking regions, do not result in loss of biological activity.
  • This invention relates not only to the novel peptides of Formula I, but also to pharmaceutical compositions comprising them, to diagnostic and therapeutic methods utilizing them, and to methods of preparing them.
  • Table I shows the ability of peptides of Formula I to inhibit the binding of human neutrophils to human P- selectin
  • Preferred peptides of this invention are those of Formula I wherein, together or independently: R 1 is hydrogen or acetyl (Ac) ; X is selected from a group consisting of Ser, Thr-Lys-Ala-Tyr, Pro-Met, Ala-Tyr or null, signifying no amino acid; X 1 is selected from a group consisting of Cys- Gln, Cys-Arg or null, signifying no amino acid; and R 2 is OH or NH 2 .
  • peptides include the following: (SEQ ID NO:l) Ser-Thr-Lys-Ala-Tyr-Ser-Trp-Asn-Ile-Ser-
  • alkyl includes branched, straight-chain, and cyclic saturated hydrocarbons.
  • lower alkyl means an alkyl having from one to six carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, cyclopentylmethyl and hexyl .
  • alkanoyl means an alkyl having from one to six carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, cyclopentylmethyl and hexyl .
  • alkanoyl means an alkyl having from one to six carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopenty
  • R 7 is a alkyl group.
  • aroyl means ' wherein R 8 is an aryl group.
  • aryl means an aromatic or heteroaromatic structure having between one and three rings, which may or may not be ring fused structures, and are optionally substituted with halogens, carbons, or other heteroatoms such as nitrogen (N) , sulfur (S) , phosphorus (P) , and boron (B) .
  • alkoxycarbonyl means
  • R 9 is a lower alkyl group.
  • aryloxycarbonyl means
  • R 10 is an aryl and arylmethyl group.
  • Halogen refers to fluorine, chlorine, bromine or iodine.
  • terminal ⁇ -amino group of X refers to the ⁇ -araino group of the N-terminal amino acid of X.
  • the peptides of Formula I can be used in the form of the free peptide or a pharmaceutically acceptable salt.
  • Amine salts can be prepared by treating the peptide with an acid according to known methods.
  • Suitable acids include inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, naphthalenesulfonic acid, and sulfanilic acid.
  • Carboxylic acid groups in the peptide can be converted to a salt by treating the peptide with a base according to known methods .
  • Suitable bases include inorganic bases such as sodium hydroxide, ammonium hydroxide, and potassium hydroxide, and organic bases such as mono-, di-, and tri-alkyl and aryl amines (e.g., triethylamine, diisopropylamine, methylamine, and dimethylamine and optionally substituted mono-, di, and tri-ethanolamines .
  • amino acid components of the peptides and certain materials used in their preparation are identified by abbreviations for convenience. These abbreviations are as follows:
  • Amino acids preceeded by L- or D- refer, respectively, to the L- or D- enantiomer of the amino acid, whereas amir- acids not preceeded by L- or D- refer to the L- enantiomer.
  • the peptides can generally be prepared following knew: techniques, as described, for example, in the cited publications, the teachings of which are specifically incorporated herein. In a preferred method, the peptides ar. prepared following the solid-phase synthetic technique initially described by Merrifield in J.Amer.Chem.Soc ⁇ , 85, 2149-2154 (1963) . Other techniques may be found, for example, in M. Bodanszky, et al, Peptide Synthesis, second edition, (John Wiley & Sons, 1976) , as well as in other reference works known to those skilled in the art .
  • N-terminal acetylation on the deprotected N ⁇ -amino group of peptides synthesized using either Boc or FMOC strategies can be accomplished with 10% Ac 2 0 and 5% DIEA in NMP, followed by washing of the peptide resin with NMP and/or CH 2 C1 2 .
  • the peptides can also be prepared using standard genetic engineering techniques known to those skilled in the art.
  • the peptide can be produced enzymatically by inserting nucleic acid encoding the peptide into an expression vector, expressing the DNA, and translating the DNA into the peptide in the presence of the required amino acids.
  • the peptide is then purified using chromatographic or electrophoretic techniques, or by means of a carrier protein which can be fused to, and subsequently cleaved from, the peptide by inserting into the expression vector in phase with the peptide encoding sequence a nucleic acid sequence encoding the carrier protein.
  • the fusion protein-peptide may be isolated using chromatographic, electrophoretic or immunological techniques (such as binding to a resin via an antibody to the carrier protein) .
  • the peptide can be cleaved using chemical methodology or enzymatically, as by, for example, hydrolases .
  • Peptides of Formulas I can also be prepared using solution methods, by either stepwise or fragment condensations.
  • An appropriately alpha amino-protected amino acid is coupled to an appropriately alpha carboxyl protected amino acid (such protection may not be required depending on the coupling method chosen) using diimides, symmetrical or unsymmetrical anhydrides, BOP, or other coupling reagents or techniques known to those skilled in the art. These techniques may be either or enzymatic.
  • alpha amino and/or alpha carboxyl protecting groups are removed and the next suitably protected amino acid or block of amino acids are coupled to extend the growing peptide.
  • Various combinations of protecting groups and of chemical and/or enzymatic techniques and assembly strategies can be used in each synthesis .
  • compositions of this invention comprise a pharmaceutically acceptable carrier or diluent and an effective quantity of one or more of the peptides of Formula I or an acid or base salt thereof.
  • the carrier or diluent may take a wide variety of forms depending on the form of preparation desired for administration, e.g., sublingual, rectal, nasal, oral, or parenteral .
  • any of the usual pharmaceutical media may be employed, for example, waters, oils, alcohols, flavoring agents, preservatives, and coloring agents, to make an oral liquid preparation (e.g., suspension, elixir, or solution) or with carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, and disintegrating agents, to make an oral solid preparation (e.g., powder, capsule, or tablet) .
  • Controlled release forms or enhancers to increase bioavailability may also be used. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed. If desired, tablets may be sugar coated or enteric coated by standard techniques.
  • the carrier will usually be sterile water, although other ingredients to aid solubility or as preservatives may be included.
  • injectable suspensions may also be prepared, in which case appropriate liquid carriers and suspending agents can be employed.
  • the peptides can also be administered locally at a wound or inflammatory site by topical application of a solution or cream.
  • the peptide may be administered in liposomes or microspheres (or microparticles) .
  • Methods for preparing liposomes and microspheres for administration to a patient are known to those skilled in the art.
  • U.S. Patent No. 4,789,734 describes methods for encapsulating biological materials in liposomes. Essentially, the material is dissolved in an aqueous solution, the appropriate phospholipids and lipids added, along with surfactants if required, and the material dialyzed or sonicated, as necessary.
  • a review of known methods is by G. Gregoriadis, Chapter 14, “Liposomes", Drug Carriers in Biology and Medicine, pp. 287-341 (Academic Press, 1979) .
  • Microspheres formed of polymers or proteins are well known to those skilled in the art, and can be tailored for passage through the gastrointestinal tract directly into the bloodstream.
  • the peptide can be incorporated and the microspheres, or composite of microspheres, implanted for slow release over a period of time, ranging from days to months. See, for example, U.S. Patents Nos . 4,906,474, 4,925,673 and 3,625,214.
  • the peptides are generally active when administered parenterally in amounts of at least about 1 ⁇ g/kg body weight. Effective doses by other routes of administration are generally those which result in similar blood level to i.v. doses of at least about 1 ⁇ g/Kg.
  • the peptides may be administered parenterally in amounts from about 0.01 to about 10 mg/kg body weight. Generally, the same range of dosage amounts may be used in treatment of other diseases or of conditions where inflammation is to be reduced. This dosage will be dependent, in part, on whether one or more peptides are administered.
  • a synergistic effect may be seen with combinations of peptides from different, or overlapping, regions of the lectin domain, or in combination with peptides derived from the EGF domain of P-, E- or L- selectin.
  • the peptides may be administered parenterally in amounts from about 0.01 to about 10 mg/kg body weight.
  • the same range of dosage amounts may be used in treatment of other diseases or of conditions where inflammation is to be reduced. This dosage will be dependent, in part, on whether one or more peptides are administered.
  • a synergistic effect may be seen with combinations of peptides from different, or overlapping, regions of the lectin domain, or in combination with peptides derived form the EGF domain of P-selectin.
  • Methods for Demonstrating Binding Peptides that are biologically active are those which inhibit binding of neutrophils, monocytes, subsets of lymphocytes or other cells to P-selectin, or which inhibit leukocyte adhesion to endothelium that is mediated by ELAM-1 and/or the homing receptor.
  • Peptides can be screened for their ability to inhibit adhesion to cells, for example, neutrophil adhesion to purified P-selectin immobilized on plastic wells, using the assay described by Geng, et al. , Nature 343, 757-760 (1990 .
  • Human neutrophils are isolated from heparinized whole blood by density gradient centrifugation on Mono-Poly resolving media, Flow Laboratories. Neutrophil suspension. " are greater than 98% pure and greater than 95% viable by trypan blue exclusion.
  • neutrophils a - suspended at a concentration of 2 x 10 6 cells/mL in Hanks' balanced salt solution containing 1.26 mM Ca 2+ and 0.81 mM Mg 2+ (HBSS, Gibco) with g mg/mL human serum albumin (HBSS/HSA) .
  • Adhesion assays are conducted in triplicate in 96-well microtiter plates, Corning, incubated at 4°C overnight with 50 microliters of various protein solutions.
  • P-selectin is isolated from hum'an platelet lysates by immunoaffinity chromatography on antibody S12-SepharoseTM and ion-exchange chromatography on a Mono-QTM column (FLPC, Pharmacia Fine Chemicals) , as follows. Outdated human platelet packs (100 units) obtained from a blood bank and stored at 4°C are pooled, adjusted to 5mM EDTA at pH 7.5, centrifuged at 4,000 rpm for 30 minutes in 1 liter bottles, then washed three times with 1 liter of 0.1 M NaCl, 20 mM Tris pH 7.5 (TBS) , 5 mM EDTA, 5 mM benzamidine.
  • TBS Tris pH 7.5
  • the pellets are then resuspended in a minimum amount of wash buffer and made lmM in DIFP, then frozen in 50 mL screwtop tubes at -80°C.
  • the frozen platelets are thawed and resuspended in 50 mL TBS, 5 mM benzamidine, 5 mM EDTA pH 7.5, 100 M leupeptin.
  • the suspension is frozen and thawed two times in a dry ice-acetone bath using a 600 mL lyophilizing flask, then homogenized in a glass/teflon mortar and pestle and made 1 mM in DIFP.
  • the NaCl concentration is adjusted to 0.5 M with a stock solution of 4 M NaCl .
  • the extraction procedure is repeated with the pellet and the supernatant is combined with the first supernatant.
  • the combined extracts which contain the membrane form of P-selectin, are adjusted to 0.5 M NaCl.
  • the soluble fraction (0.5 M NaCl wash) and the membrane extract (also adjusted to 0.5 M NaCl) are absorbed with separate pools of the monoclonal antibody S12 (directed to P-selectin) previously coupled to Affigel (Biorad) at 5 mg/mL for 2 hours at 4°C. After letting the resins settle, the supernatants are removed.
  • the S12 Affigel containing bound GMP-140 is then loaded into a column and washed overnight at 4°C with 400 mL of 0.5 M NaCl, 20 mM Tris pH 7.5, 0.01% Lubrol PX.
  • Bound P-selectin is eluted from the S12 Affigel with 100 mL of 80% ethylene glycol, 1 mM MES pH 6.0, 0.01% Lubrol PX. Peak fractions with absorbance at 280 nm are pooled. Eluates are dialyzed against TBS with 0.05% Lubrol, then applied to a Mono Q column (FPLC from Pharmacia) . The concentrated protein is step eluted with 2 M NaCl, 20 mM Tris pH 7.5 (plus 0.05% Lubrol PX for the membrane fraction) . Peak fractions are dialyzed into TBS pH 7.5 (plus 0.05% Lubrol PX for the membrane fraction) .
  • P-selectin is plated at 5 micrograms/mL and the control proteins: human serum albumin (Alb) , platelet glycoprotein Hb/IIIa (lib) , von Willebrand factor (vWF) , fibrinogen (FIB) , thrombomodulin (TM) , gelatin (GEL) or human serum (HS) , are added at 50 micrograms/mL. All wells are blocked for 2 hours at 22°C with 300 microliters HBSS containing 10 mg/mL HSA, then washed three times with HBSS containing 0.1% Tween-20 and once with HBSS. Cells (2 x 10 5 per well) are added to the wells and incubated at 22°C for 20 minutes.
  • the wells are then filled with HBSS/HSA, sealed with acetate tape (Dynatech) , and centrifuged inverted at 150 g for 5 minutes . After discarding nonadherent cells and supernates, the contents of each well are solubilized with 200 microliters 0.5% hexadecyltrimethylammonium bromide, Sigma, in 50 mM potassium phosphate, pH. 6.0, and assayed for myeloperoxidase activity, Ley, et al . , Blood 73, 1324-1330 (1989) . The number of cells bound is derived from a standard curve of myeloperoxidase activity versus numbers of cells.
  • the cells release less than 5% of total myeloperoxidase and lactate dehydrogenase. Inhibition is read as a lower percent adhesion, so that a value of 5% means that 95% of the specific adhesion was inhibited.
  • selectins have several functions related to leukocyte adherence, inflammation, and coagulation, compounds which interfere with binding of P-selectin, E-selectin or L- selectin can be used to modulate these responses.
  • the peptides can be used to competitively inhibit leukocyte adherence by competitively binding to P- selectin receptors on the surface of leukocytes.
  • This kind of therapy would be particularly useful in acute situations where effective, but transient, inhibition of leukocyte- mediated inflammation is desirable.
  • Chronic therapy by infusion of the peptides may also be feasible in some circumstances.
  • An inflammatory response may cause damage to the host if unchecked, because leukocytes release many toxic molecules that can damage normal tissues. These molecules include proteolytic enzymes and free radicals. Examples of pathological situations in which leukocytes can cause tissue damage include injury from ischemia and reperfusion, bacterial sepsis and disseminated intravascular coagulation, adult respiratory distress syndrome, tumor metastasis, rheumatoid arthritis and atherosclerosis.
  • Reperfusion injury is a major problem in clinical cardiology.
  • Therapeutic agents that reduce leukocyte adherence in ischemic myocardium can significantly enhance the therapeutic efficacy of thrombolytic agents.
  • Thrombolytic therapy with agents such as tissue plasminogen activator or streptokinase can relieve coronary artery obstruction in many patients with severe myocardial ischemia prior to irreversible myocardial cell death.
  • tissue plasminogen activator or streptokinase can relieve coronary artery obstruction in many patients with severe myocardial ischemia prior to irreversible myocardial cell death.
  • many such patients still suffer myocardial neurosis despite restoration of blood flow.
  • This "reperfusion injury” is known to be associated with adherence of leukocytes to vascular endothelium in the ischemic zone, presumably in part because of activation of platelets and endothelium by thrombin and cytokines that makes them adhesive for leukocytes (Romson et al . , Circulation 67: 1016-1023 (1983)) . These adherent leukocytes can migrate through the endothelium and destroy ischemic myocardium just as it is being rescued by restoration of blood flow.
  • Adult respiratory distress syndrome is a devastating pulmonary disorder occurring in patients with sepsis or following trauma, which is associated with widespread adherence and aggregation of leukocytes in the pulmonary circulation. This leads to extravasation of large amounts of plasma into the lungs and destruction of lung tissue, both mediated in large part by leukocyte products.
  • LAK cells interleukin-2 treated LAK cells (lymphokine-activated lymphocytes) .
  • LAK cells are known to adhere to vascular walls and release products that are presumably toxic to endothelium. Although the mechanism by which LAK cells adhere to endothelium is now known, such cells could potentially release molecules that activate endothelium and then bind to endothelium by mechanisms similar to those operative in neutrophils. Tumor cells from many malignancies (including carcinomas, lymphomas, and sarcomas) can metastasize to distant sites through the vasculature.
  • E- selectin might be involved in tumor metastasis by mediating the adhesion of a colon carcinoma cell line (HT-20) to activated endothelial cells in vi tro .
  • HT-20 colon carcinoma cell line
  • Platelet-leukocyte interactions are believed to be important in atherosclerosis . Platelets might have a role in recruitment of monocytes into atherosclerotic plaques; the accumulation of monocytes is known to be one of the earliest detectable events during atherogenesis . Rupture of a fully developed plaque may not only lead to platelet deposition and activation and the promotion of thrombus formation, but also the early recruitment of neutrophils to an area of ischemia.
  • Another area of potential application is in the treatment of rheumatoid arthritis.
  • the criteria for assessing response to therapeutic modalities employing these peptides, and, hence, effective dosages of the peptides of this invention for treatment ar. dictated by the specific condition and will generally follow standard medical practices.
  • the criteria for the effective dosage to prevent extension of myocardial infarction would be determined by one skilled in the art by looking at marker enzymes of myocardial necrosis in the plasma, by monitoring the electrocardiogram, vital signs, and clinical response.
  • For treatment of acute respiratory distress syndrome one would examine improvements in arterial oxygen, resolution of pulmonary infiltrates, and clinical improvement as measured by lessened dyspnea and tachypnea.
  • the effective dosage would be based on the clinical response and specific measurements of function of vital organs such as the liver and kidney following restoration of blood pressure. Neurologic function would be monitored in patients with stroke. Specific tests are used to monitor the functioning of transplanted organs; for example, serum creatinine, urine flow, and serum electrolytes in patients undergoing kidney transplantation.
  • the peptides can also be used for the detection of human disorders in which the ligands for the selectins might be defective. Such disorders would most likely be seen in patients with increased susceptibility to infections in which leukocytes might not be able to bind to activated platelets or endothelium.
  • Cells to be tested usually leukocytes, are collected by standard medically approved techniques and screened. Detection systems include ELISA procedures, binding of radiolabeled antibody to immobilized activated cells, flow cytometry, or other methods known to those skilled in the art. Inhibition of binding in the presence and absence of the lectin domain peptides can be used to detect defects or alterations in selectin binding. For selectins, such disorders would most likely be seen in patients with increased susceptibility to infections in which leukocytes would have defective binding to platelets and endothelium because of deficient leukocyte ligands for P- selectin.
  • the peptide is labeled radioactively, with a fluorescent tag, enzymatically, or with electron dense material such as gold for electron microscopy.
  • the cells to be examined usually leukocytes, are incubated with the labeled peptides and binding assessed by methods described above with antibodies to P-selectin, or by other methods known to those skilled in the art. If ligands for P-, E- or L-selectin are also found in the plasma, they can also be measured with standard ELISA or radioimmunoassay procedures, using labeled P-, E- or L-selectin-derived peptide instead of antibody as the detecting reagent.
  • the peptides can also be useful in in vivo imaging of concentrations of cells bearing selectin ligands.
  • Cells expressing selectin ligands whose abnormally high local concentrations or presence within the body such as cancer cells, is indicative of a disorder can be imaged using labeled peptides.
  • These labels may be either intrinsic or extrinsic to the structure of the specific selectin peptide and may include, but not be limited to high energy emitters such as 1:L1 In or non-radioactive dense atoms to enhance x-ray contrast.
  • the peptide was prepared on an ABI Model 43IA Peptide Synthesizer using Version 1.12 of the standard Boc software.
  • the peptide was cleaved from the resin using 15 mL of
  • the crude peptide was purified on a Vydac C-18 column
  • the peptide was prepared on an ABI Model 43IA Peptide Synthesizer using Version 1.12 of the standard BOC software. 4-methyl benzhydrylamine resin (0.625 g, 0.5 mmol) was used in the synthesis. The final weight of the resin was 1.74 g. The peptide was cleaved from the resin (1.74 g) using 17 mL of HF and 1.7 mL of anisole for 60 min at 0°C. The resin was washed with ether and the peptide extracted with 50% TFA in DCM to give 359 mg of crude peptide.
  • the crude peptide (359 mg) was initially purified on a Vydac C-18 column (15 ⁇ , 5 x 25 cm) eluting with a 10-50% gradient of 80% acetonitrile in 0.1% TFA over 120 min at a flow rate of 15 mL per min. It was finally purified on the same system using a 10-40% gradient of 80% acetonitrile in 0.1% TFA. Fractions were collected, analyzed by HPLC and pure fractions pooled and lyophilized to give 17 mg.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de nouveaux peptides présentant comme région de noyau des parties de la séquence d'acides aminés 11-18 de P-sélectine, E-sélectine ou L-sélectine. L'invention concerne également des compositions pharmaceutiques comprenant les peptides de l'invention, ainsi que des procédés diagnostiques et thérapeutiques utilisant lesdits peptides et des compositions pharmaceutiques de l'invention.
PCT/US1993/008436 1992-09-08 1993-09-08 Inhibiteurs peptidiques de fixation de la selectine WO1994005269A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94164992A 1992-09-08 1992-09-08
US941,649 1992-09-08

Publications (1)

Publication Number Publication Date
WO1994005269A1 true WO1994005269A1 (fr) 1994-03-17

Family

ID=25476832

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/008436 WO1994005269A1 (fr) 1992-09-08 1993-09-08 Inhibiteurs peptidiques de fixation de la selectine

Country Status (1)

Country Link
WO (1) WO1994005269A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5440015A (en) * 1992-07-21 1995-08-08 Glycomed Incorporated Selectin peptide medicaments for treating disease
EP0759781A1 (fr) * 1994-06-03 1997-03-05 Center For Blood Research, Inc. Procede de traitement et de prevention de l'arteriosclerose
WO1997018790A2 (fr) * 1995-11-22 1997-05-29 The Research And Development Institute, Inc. Agents therapeutiques et de diagnostic pour traiter les infections microbiennes
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
EP0804467A1 (fr) * 1995-01-10 1997-11-05 Ludwig Institute For Cancer Research Molecules d'acide nucleique isoles et tronques codant pour l'antigene gage de rejet des tumeurs
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US6254852B1 (en) 1999-07-16 2001-07-03 Dupont Pharmaceuticals Company Porous inorganic targeted ultrasound contrast agents
EP1288222A1 (fr) * 2001-09-03 2003-03-05 Yamanouchi Europe B.V. Composés peptidiques liants spécifiquement au P-selectin
US6916460B2 (en) 1999-09-13 2005-07-12 Bristol-Myers Squibb Pharma Company Macrocyclic chelants for metallopharmaceuticals
US7317104B2 (en) 2003-06-13 2008-01-08 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US7319149B2 (en) 2003-06-13 2008-01-15 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
WO2010092114A1 (fr) 2009-02-13 2010-08-19 Guerbet Utilisation de tampons pour la complexation de radionucléides
WO2012084981A1 (fr) 2010-12-20 2012-06-28 Guerbet Nanoemulsion de chelate pour irm
WO2013045333A1 (fr) 2011-09-26 2013-04-04 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
WO2014114724A1 (fr) 2013-01-23 2014-07-31 Guerbet Magneto-emulsion vectorisee
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
WO2020007822A1 (fr) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Nanoparticules de bismuth métallique (0), procédé de fabrication et utilisations de celles-ci

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CELL, Vol. 56, issued 24 March 1989, G.I. JOHNSTON et al., "Cloning of GMP-140, a Granule Membrane Protein of Platelets and Endothelium: Sequence Similarity to Proteins Involved in Cell Adhesion and Inflamation", pages 1033-1044. *
CLIN. IMM. PATH., Vol. 60, issued 1991, M. PATARROYO, "Leukocyte Adhesion in Host Defense and Tissue Injury", pages 333-348. *
EUR. J. IMMUNOL., Volume 22, issued 1992, N.K. DAMLE et al., "GMP-140 (P-Selectin/CD62) Binds to Chronically Stimulated but not Resting CD4+ T Lymphocytes and Regulates their Production of Proinflammatory Cytokines", pages 1789-93. *
INTERNATIONAL IMMUNOLOGY, Volume 2, (10), A, AGER et al., "Use of Synthetic Peptides to Probe Lymphocyte-High Endothelial Cell Interactions. Lymphocytes Recognize a Ligand on the Endothelial Surface which Contains the CS1 Adhesion Motif", pages 921-928. *
JOUR. AMER. CHEM. SOC., Vol. 85, issued 20 July 1963, R.B. MERRIFIELD, "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide", pages 2149-2154. *
JOURN. OF BIOL. CHEM., Vol. 265, (34), issued December 1990, G.I. JOHNSTON et al., "Structure of the Human Gene Encoding Granule Membrane Protein-140, a Member of the Selectin Family of Adhesion Receptors for Leukocytes", pages 21381-21385. *
JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 266, (33), issued 25 November 1991, J-G GENG et al., "Neutrophil Recognition Requires a Ca2+ -Induced Conformational Change in the Lectin Domain of GMP-140", pages 22313-22318. *
PROC. NATL. ACAD. SCI. USA, Vol. 84, issued December 1987, BEVILACQUA et al., "Identification of Inducible Endothelial-Leukocyte Adhesion Molecule", pages 9238-9242. *
PROC. SOC. EXP. BIOL. MED., Vol. 198, No. 2, issued 1991, A. CELI et al., "PADGEM: An Adhesion Receptor for Leukocytes in Stimulated Platelets and Endothelial Cells", pages 703-709. *
SCIENCE, Volume 243, issued March 1989, BEVILACQUA et al., "Endothelial Leukocyte Adhesion Molecule 1: An Inducible Receptor for Neutrophils Related to Complement Regulatory Proteins and Lectins", pages 1160-1165. *
TRANSPLANTATION, Vol. 50, Number 4, issued October 1990, J.S. POBER et al., "The Role of Endothelial Cells in Inflammation", pages 537-550. *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5786322A (en) * 1992-05-06 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1
US5440015A (en) * 1992-07-21 1995-08-08 Glycomed Incorporated Selectin peptide medicaments for treating disease
US5858689A (en) * 1993-07-22 1999-01-12 Ludwig Institute For Cancer Research Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof
EP0759781A1 (fr) * 1994-06-03 1997-03-05 Center For Blood Research, Inc. Procede de traitement et de prevention de l'arteriosclerose
EP0759781A4 (fr) * 1994-06-03 2000-12-06 Blood Res Center Procede de traitement et de prevention de l'arteriosclerose
EP0804467A1 (fr) * 1995-01-10 1997-11-05 Ludwig Institute For Cancer Research Molecules d'acide nucleique isoles et tronques codant pour l'antigene gage de rejet des tumeurs
EP0804467A4 (fr) * 1995-01-10 1997-12-03
WO1997018790A2 (fr) * 1995-11-22 1997-05-29 The Research And Development Institute, Inc. Agents therapeutiques et de diagnostic pour traiter les infections microbiennes
WO1997018790A3 (fr) * 1995-11-22 1997-07-31 Univ Montana Res Dev Inst Agents therapeutiques et de diagnostic pour traiter les infections microbiennes
US6254852B1 (en) 1999-07-16 2001-07-03 Dupont Pharmaceuticals Company Porous inorganic targeted ultrasound contrast agents
US6916460B2 (en) 1999-09-13 2005-07-12 Bristol-Myers Squibb Pharma Company Macrocyclic chelants for metallopharmaceuticals
WO2003020753A1 (fr) * 2001-09-03 2003-03-13 Yamanouchi Europe B.V. Composes peptidiques se fixant de maniere selective a la p-selectine
US7531516B2 (en) 2001-09-03 2009-05-12 Astellas Pharma Europe B.V. Peptidic compounds selectively binding to P-selectin
EP1288222A1 (fr) * 2001-09-03 2003-03-05 Yamanouchi Europe B.V. Composés peptidiques liants spécifiquement au P-selectin
US7317104B2 (en) 2003-06-13 2008-01-08 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US7319149B2 (en) 2003-06-13 2008-01-15 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
WO2010092114A1 (fr) 2009-02-13 2010-08-19 Guerbet Utilisation de tampons pour la complexation de radionucléides
WO2012084981A1 (fr) 2010-12-20 2012-06-28 Guerbet Nanoemulsion de chelate pour irm
US9770520B2 (en) 2010-12-20 2017-09-26 Guerbet Chelate nanoemulsion for MRI
WO2013045333A1 (fr) 2011-09-26 2013-04-04 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
WO2014114724A1 (fr) 2013-01-23 2014-07-31 Guerbet Magneto-emulsion vectorisee
WO2020007822A1 (fr) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Nanoparticules de bismuth métallique (0), procédé de fabrication et utilisations de celles-ci

Similar Documents

Publication Publication Date Title
US5710123A (en) Peptide inhibitors of selectin binding
US5618785A (en) Peptide inhibitors of selectin binding
US6111065A (en) Peptide inhibitors of inflammation mediated by selectins
US5753617A (en) Peptide inhibitors of cellular adhesion
US6528487B1 (en) Peptide inhibitors of inflammation mediated by selectins
AU660627B2 (en) Functionally active selectin-derived peptide for GMP-140
US5198424A (en) Functionally active selectin-derived peptides
WO1994005269A1 (fr) Inhibiteurs peptidiques de fixation de la selectine
US6667036B2 (en) Methods of treatment using antibodies to P-selectin glycoprotein ligand
AU681369B2 (en) Glycoprotein ligand for P-selectin and methods of use thereof
US5916876A (en) Peptide inhibitors of leukocyte adhesion
US5464935A (en) Peptide inhibitors of selectin binding
US5602230A (en) Peptide inhibitors of selectin binding
WO1992020708A1 (fr) Peptides inhibiteurs de l'inflammation
EP1245575A2 (fr) Peptides fonctionellement actifs dérivés de sélectine et ligand pour GMP140

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: US

Ref document number: 1995 397100

Date of ref document: 19950307

Kind code of ref document: A

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载